<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nodgo</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал детской гематологии и онкологии (РЖДГиО)</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Pediatric Hematology and Oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-1267</issn><issn pub-type="epub">2413-5496</issn><publisher><publisher-name>LTD “Graphica”</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nodgo-464</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРЕСС-РЕЛИЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRESS RELEASE</subject></subj-group></article-categories><title-group><article-title>В России зарегистрирован препарат Гемлибра – первый в мире препарат для лечения гемофилии А с подкожным введением</article-title><trans-title-group xml:lang="en"><trans-title>Gemlibra is registered in Russia – the world’s first drug for the treatment of hemophilia A with subcutaneous administration</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editorial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>01</month><year>2019</year></pub-date><volume>5</volume><issue>4</issue><fpage>126</fpage><lpage>128</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Editorial A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nodgo.org/jour/article/view/464">https://journal.nodgo.org/jour/article/view/464</self-uri><abstract><p>В России зарегистрирован препарат Гемлибра – первый в мире препарат для лечения гемофилии А с подкожным введением.</p></abstract><trans-abstract xml:lang="en"><p>Gemlibra is registered in Russia – the world’s first drug for the treatment of hemophilia A with subcutaneous administration.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению препарата Гемлибра, ЛП-005110.</mixed-citation><mixed-citation xml:lang="en">Инструкция по медицинскому применению препарата Гемлибра, ЛП-005110.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Oldenburg J., Mahlangu J.N., Kim B. et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.</mixed-citation><mixed-citation xml:lang="en">Oldenburg J., Mahlangu J.N., Kim B. et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Young G. et al. Emicizumab-kxwh prophylaxis reduces bleeds among children with hemophilia A. Abstract 85. Presented at: ASH Annual Meeting and Exposition; Dec. 9–12, 2017; Atlanta.</mixed-citation><mixed-citation xml:lang="en">Young G. et al. Emicizumab-kxwh prophylaxis reduces bleeds among children with hemophilia A. Abstract 85. Presented at: ASH Annual Meeting and Exposition; Dec. 9–12, 2017; Atlanta.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Всемирная Федерация Гемофилии. Рекомендации по лечению гемофилии (на англ.), 2012 [Интернет; июль 2018]. Доступно по ссылке: http://www1.wfh.org/publications/fi les/pdf-1472.pdf.</mixed-citation><mixed-citation xml:lang="en">Всемирная Федерация Гемофилии. Рекомендации по лечению гемофилии (на англ.), 2012 [Интернет; июль 2018]. Доступно по ссылке: http://www1.wfh.org/publications/fi les/pdf-1472.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Зозуля Н.И., Кумскова М.А., Полянская Т.Ю., Свирин П.В. Клинические рекомендации по диагностике и лечению гемофилии, 2018. Доступно по ссылке: https://xn--c1aejaoeo2c6f.xn--p1ai/law/law-stand/786-gemofi liya-klinicheskie-rekomendacii.html.</mixed-citation><mixed-citation xml:lang="en">Зозуля Н.И., Кумскова М.А., Полянская Т.Ю., Свирин П.В. Клинические рекомендации по диагностике и лечению гемофилии, 2018. Доступно по ссылке: https://xn--c1aejaoeo2c6f.xn--p1ai/law/law-stand/786-gemofi liya-klinicheskie-rekomendacii.html.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
